Novo Nordisk's CagriSema shows blood pressure reduction in obesity trial

Novo Nordisk (NYSE: NVO) reported that its investigational obesity treatment CagriSema demonstrated a 10.9 mmHg reduction in systolic blood pressure in a post hoc analysis of the phase 3 REDEFINE 1 trial, according to data presented at ObesityWeek in Atlanta.

The analysis showed that 40% of participants taking blood pressure medications were able to reduce or stop their medication during the 68-week trial. CagriSema is a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg administered as a weekly injection.

The treatment also reduced high-sensitivity C-reactive protein, an inflammatory marker associated with cardiovascular risk, by 68.9% compared to 55.4% with semaglutide alone and 16.0% with placebo. The reduction occurred regardless of baseline inflammation levels.

CagriSema decreased the proportion of patients at intermediate-to-high risk of developing atherosclerotic cardiovascular disease within 10 years, according to the company. A separate trial called REDEFINE 3 is ongoing to evaluate cardiovascular outcomes in patients with established heart disease.

The REDEFINE 1 trial included 3,417 adults with obesity or overweight with comorbidities but without type 2 diabetes. Adverse events were primarily gastrointestinal, with nausea occurring in 55% of CagriSema patients versus 12.6% with placebo. Discontinuation due to adverse events occurred in 6% of CagriSema patients compared to 3.7% with placebo.

CagriSema is not approved in the United States or European Union. The company is investigating the treatment for both obesity and type 2 diabetes in separate clinical programs.

You May Also Be Interested In

• AstraZeneca's camizestrant fails primary endpoint in breast cancer trial
• The Generation Essentials Group receives NYSE non-compliance notice
• Cronos Group extends cannabis acquisition deadline to October 2026